| Project/Area Number |
25461801
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Fukushima Medical University (2015)
Gunma University (2013-2014) |
|---|
Principal Investigator |
oriuchi noboru 福島県立医科大学, 公私立大学の部局等, 教授 (40292586)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TOMINAGA Hideyuki 福島県立医科大学, 先端臨床医研究センター, 准教授 (00393348)
KAIRA Kyouichi 群馬大学大学院医学系研究科, がん治療臨床開発学講座, 教授 (40400783)
OSHIMA Yasuhiro 量子科学技術研究開発機構, 量子ビーム科学研究部門, 博士研究員 (00588676)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | LAT1 / アミノ酸トランスポーター / ポジトロンCT / 18F-FAMT / 分子標的治療 / PET / コンパニオン診断 / ASCT2 / 胆管細胞がん / 胆管がん / mTOR |
|---|
| Outline of Final Research Achievements |
The present studies disclosed roles of L-type amino acid transporter 1 (LAT1) for growth and prognosis in a variety of cancer, suggesting that LAT1 would be a molecular target of anti-cancer therapy. Clinical significance of L-[3-18F]-α-methyl tyrosine (18F-FAMT) PET have been examined. 18F-FAMT is accumulated in tumor specifically via LAT1, therefore, 18F-FAMT PET would be a marker of LAT1 expression. Uptake of 18F-FAMT could differentiate between benign lesions and malignant tumors. Additionally, the high uptake of 18F-FAMT could predict poor outcome of patients. 18F-FAMT PET would be an imaging marker of LAT1-targeted therapy.
LAT1 inhibitor 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) inhibited [14C] L-leucine uptake in human cholangiocarcinoma cell line named HuCCT1, and decreased proliferation of cells and growth of xenograft in nude mice. Moreover, prognostic potential of ASC amino-acid transporter 2 (ASCT2) have been shown in biliary tract cancers.
|
